TABLE 2.
Effect of LpL on FFA composition of human VLDL fractions
| VLDL EFA | VLDL NEFAa | VLDL+LpL NEFAa | LpL Released NEFA | LpL Released NEFA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| nmol/mg TG | % | |||||||||
| Saturated fatty acid | ||||||||||
| C14:0 | 694 ± 13 | 8.43 ± 1.2 | 16.7 ± 0.98b | 8.27 ± 0.98 | 1 | |||||
| C15:0 | 75.1 ± 1.6 | 0.622 ± 0.22 | 1.78 ± 0.16b | 1.16 ± 0.16 | 2 | |||||
| C16:0 | 9240 ± 410 | 148 ± 22 | 268 ± 19b | 120 ± 19 | 1 | |||||
| C17:0 | 64.7 ± 1.9 | ND | ND | ND | 1 | |||||
| C18:0 | 1350 ± 59 | 38.3 ± 7.1 | 62 ± 6.3b | 23.8 ± 6.3 | 2 | |||||
| C19:0 | 13.2 ± 0.23 | ND | ND | ND | ND | |||||
| C20:0 | 10.9 ± 0.43 | ND | ND | ND | ND | |||||
| C21:0 | 1.71 ± 0.12 | ND | ND | ND | ND | |||||
| C22:0 | 5.15 ± 0.25 | ND | ND | ND | ND | |||||
| C24:0 | 3.94 ± 0.24 | ND | ND | ND | ND | |||||
| MUFA | ||||||||||
| C14:1n5 | 50 ± 1.6 | 0.951 ± 0.071 | 1.31 ± 0.072b | 0.361 ± 0.072 | 1 | |||||
| C16:1n7t | 140 ± 5.2 | 0.564 ± 0.042 | 2.57 ± 0.29b | 2.01 ± 0.29 | 1 | |||||
| C16:1n7 | 1,030 ± 61 | 10.7 ± 1.7 | 19.9 ± 1.5b | 9.18 ± 1.5 | 1 | |||||
| C18:1n9t | 65.6 ± 3.7 | 2.07 ± 0.66 | 4.39 ± 0.65b | 2.32 ± 0.65 | 4 | |||||
| C18:1n9/1n7t | 7020 ± 300 | 98.7 ± 13 | 167 ± 10b | 67.8 ± 10 | 1 | |||||
| C18:1n7/1n6 | 1,170 ± 49 | 18.2 ± 2.7 | 30.8 ± 2.3b | 12.6 ± 2.3 | 1 | |||||
| C20:1n9t/1n12 | 8.24 ± 0.55 | ND | ND | ND | ND | |||||
| C20:1n9 | 28.3 ± 0.81 | 1.17 ± 0.088 | 1.58 ± 0.073b | 0.411 ± 0.072 | 1 | |||||
| PUFA | ||||||||||
| C18:2(9t,12t)n6 | 42.8 ± 0.72 | 0.164 ± 0.063 | 0.681 ± 0.089b | 0.518 ± 0.089 | 1 | |||||
| C18:2n6 | 6340 ± 270 | 86.1 ± 13 | 134 ± 11b | 48.2 ± 11 | 1 | |||||
| C18:3n6 | 121 ± 2.1 | 1.69 ± 0.16 | 2.15 ± 0.14 | 0.465 ± 0.14 | 0 | |||||
| C18:2(9ct,11t)n6 | 115 ± 2.7 | 0.226 ± 0.046 | 1.37 ± 0.24b | 1.15 ± 0.24 | 1 | |||||
| C18:3n3 | 213 ± 4.2 | ND | ND | 2.31 ± 0.37 | 1 | |||||
| C18:4n3 | 10.9 ± 0.37 | ND | ND | ND | ND | |||||
| C20:2n6 | 34.1 ± 0.63 | ND | ND | ND | ND | |||||
| C20:3n6 | 190 ± 4.6 | 4.96 ± 1 | 7.66 ± 1.1 | 2.7 ± 1.1 | 1 | |||||
| C20:4n6 | 732 ± 29 | 28 ± 5 | 36.8 ± 4.5 | 8.83 ± 4.5 | 1 | |||||
| C20:3n3 | 4.78 ± 0.25 | ND | ND | ND | ND | |||||
| C20:3n9 | 34.6 ± 1 | ND | ND | ND | ND | |||||
| C20:4n3 | 11.8 ± 0.3 | 0.628 ± 0.033 | 0.741 ± 0.038 | 0.113 ± 0.038 | 1 | |||||
| C20:5n3 | 56.2 ± 1.1 | 2.04 ± 0.19 | 2.42 ± 0.21 | 0.38 ± 0.21 | 1 | |||||
| C22:4n6 | 43.6 ± 1.1 | 1.28 ± 0.15 | 1.81 ± 0.15b | 0.535 ± 0.15 | 1 | |||||
| C22:5n6 | 37.7 ± 0.79 | 1.85 ± 0.22 | 2.27 ± 0.19 | 0.578 ± 0.15 | 2 | |||||
| C22:5n3 | 70.2 ± 2.1 | 2.18 ± 0.25 | 2.75 ± 0.21 | 0.568 ± 0.21 | 1 | |||||
| C22:6n3 | 195 ± 5.5 | 8.65 ± 1.5 | 11.7 ± 1.3 | 3.05 ± 1.3 | 2 | |||||
| C24:6n3 | 5.78 ± 0.25 | 0.447 ± 0.039 | 0.479 ± 0.041 | 0.097 ± 0.029 | 2 | |||||
TG, triglyceride; EFA, esterified fatty acid. Values are presented as blank corrected mean ± SEM (n = 4). Data were compared by complete weighted least-squares means analysis.
a
Multiplying NEFA nmol/mg TG concentrations by 4 will yield solution concentrations in μM.
b
Significant release of EFA (P < 0.05).